TRIB2 and central nervous system cancer: The data indicated that TRIB2 and MAP3K1 were likely to be enriched in GBM and grade III glioma (TRIB2High/MAP3K1High samples accounted for 72.09% in GBM and 63.16% in grade III glioma) compared with grade I and grade II glioma (Figure 6).